Replies to post #110333 on NanoViricides Inc. (NNVC)

[bloomvest]

Exactly KMBJN. Buy More!!!! When you crunch the numbers, lets only consider North American, European, Western markets.

Over-the-counter pharmaceutical sales globally are projected to be US$138 billion in 2017. 36% of those sales are cough, cold, analgesics, and headache medications --that is, medications associated with flu viruses. That is not the total market, but it gives an idea of the potential sales for a Flucide. People will choose to be cured as opposed to relief medicated. Global sales, even without a pandemic could still capture 1/4 of the available market that currently goes toward OTC flu related medicines.

So, $9 billion as a potential market for Flucides. How would that translate into share value?

An even greater percentage of the population will have STD's.

So, $10 billion as a potential market for Herpescides. How would that translate into share value?


Assuming a P/E of a modest 20/1 for a pharma with earnings of only 10% net of gross and we have $480 a share for Flucide and Herpescide. I'm still sticking with the Nanoviricide 5 year Timeline. Anything sooner is simply a bonus.